• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SLC14A1 基因在前列腺癌生化复发中的作用研究。

Study on the role of SLC14A1 gene in biochemical recurrence of prostate cancer.

机构信息

Department of Anesthesiology, Second Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

Department of Urology, Xiangya Hospital, Central South University, Changsha, 410008, Hunan, China.

出版信息

Sci Rep. 2022 Oct 18;12(1):17064. doi: 10.1038/s41598-022-20775-7.

DOI:10.1038/s41598-022-20775-7
PMID:36257969
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9579171/
Abstract

Prostate cancer (PCa) is a common malignant disease among men and biochemical recurrence (BCR) is considered to be a decisive risk factor for clinical recurrence and PCa metastasis. Clarifying the genes related to BCR and its possible pathways is vital for providing diagnosis and treatment methods to delay the progress of BCR. An analysis of data concerning PCa from previous datasets of The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) was performed. Immunohistochemical (IHC) staining were used to evaluate the expression of SLC14A1 in prostate tissues. Kaplan-Meier analysis, Pearson correlation, and single sample Gene Set Enrichment Analysis (ssGSEA) were used to identify the potential pathway and molecular mechanism of the function of SLC14A1 in BCR of PCa. The expression of SLC14A1 is significantly reduced in prostate cancer cells and tissue comparing to normal prostate epithelial cell and para-cancerous tissue. As indicated by Kaplan-Meier analysis, High expression of SLC14A1 could increase the BCR-free survival time of PCa patients. This effect might be related to the interaction with miRNAs (has-miR-508, has-mir-514a2, and has-mir-449a) and the infiltration of B cells. SLC14A1 is a novel important gene associated with BCR of PCa, and further studies of its molecular mechanism may delay the progress of BCR.

摘要

前列腺癌(PCa)是男性常见的恶性疾病,生化复发(BCR)被认为是临床复发和 PCa 转移的决定性危险因素。阐明与 BCR 相关的基因及其可能的途径对于提供诊断和治疗方法以延缓 BCR 的进展至关重要。对来自癌症基因组图谱(TCGA)和基因表达综合数据库(GEO)的先前 PCa 数据集的数据进行了分析。使用免疫组织化学(IHC)染色来评估前列腺组织中 SLC14A1 的表达。采用 Kaplan-Meier 分析、Pearson 相关性和单样本基因集富集分析(ssGSEA)来鉴定 SLC14A1 在 PCa BCR 中的潜在通路和分子机制的功能。与正常前列腺上皮细胞和癌旁组织相比,SLC14A1 在前列腺癌细胞和组织中的表达明显降低。Kaplan-Meier 分析表明,SLC14A1 的高表达可以增加 PCa 患者的 BCR 无复发生存时间。这种作用可能与 miRNA(has-miR-508、has-mir-514a2 和 has-mir-449a)的相互作用和 B 细胞的浸润有关。SLC14A1 是与 PCa BCR 相关的一个新的重要基因,对其分子机制的进一步研究可能会延缓 BCR 的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccf4/9579171/d6954ce7b7ad/41598_2022_20775_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccf4/9579171/b2932e6b96ad/41598_2022_20775_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccf4/9579171/7a2afa579b4e/41598_2022_20775_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccf4/9579171/d6954ce7b7ad/41598_2022_20775_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccf4/9579171/b2932e6b96ad/41598_2022_20775_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccf4/9579171/7a2afa579b4e/41598_2022_20775_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ccf4/9579171/d6954ce7b7ad/41598_2022_20775_Fig3_HTML.jpg

相似文献

1
Study on the role of SLC14A1 gene in biochemical recurrence of prostate cancer.SLC14A1 基因在前列腺癌生化复发中的作用研究。
Sci Rep. 2022 Oct 18;12(1):17064. doi: 10.1038/s41598-022-20775-7.
2
Meta-analysis of miRNA expression profiles for prostate cancer recurrence following radical prostatectomy.前列腺癌根治术后复发的miRNA表达谱的Meta分析。
PLoS One. 2017 Jun 26;12(6):e0179543. doi: 10.1371/journal.pone.0179543. eCollection 2017.
3
ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.ZNF154 是一种很有前途的诊断生物标志物,可预测前列腺癌的生化复发。
Gene. 2018 Oct 30;675:136-143. doi: 10.1016/j.gene.2018.06.104. Epub 2018 Jul 4.
4
High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.ASPM的高表达与前列腺癌患者的肿瘤进展相关,并预示着不良预后。
Int Urol Nephrol. 2017 May;49(5):817-823. doi: 10.1007/s11255-017-1545-7. Epub 2017 Feb 17.
5
Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.微小RNA-128的组织和血清水平对人类前列腺癌的预后影响
Int J Clin Exp Pathol. 2015 Jul 1;8(7):8394-401. eCollection 2015.
6
Association of microRNA-126 expression with clinicopathological features and the risk of biochemical recurrence in prostate cancer patients undergoing radical prostatectomy.微小 RNA-126 表达与接受根治性前列腺切除术的前列腺癌患者临床病理特征及生化复发风险的相关性研究。
Diagn Pathol. 2013 Dec 18;8:208. doi: 10.1186/1746-1596-8-208.
7
miR-196a-mediated downregulation of p27 protein promotes prostate cancer proliferation and relates to biochemical recurrence after radical prostatectomy.miR-196a 通过下调 p27 蛋白促进前列腺癌的增殖,并与根治性前列腺切除术后的生化复发有关。
Prostate. 2020 Sep;80(12):1024-1037. doi: 10.1002/pros.24036. Epub 2020 Jul 6.
8
Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.丝氨酸蛋白酶抑制剂家族G1(SERPING1)在前列腺癌中的表达降低有助于区分高危前列腺癌并预测恶性进展。
Urol Oncol. 2018 Aug;36(8):366.e1-366.e9. doi: 10.1016/j.urolonc.2018.05.021. Epub 2018 Jun 19.
9
Down-regulation of SLC14A1 in prostate cancer activates CDK1/CCNB1 and mTOR pathways and promotes tumor progression.前列腺癌细胞中 SLC14A1 的下调激活 CDK1/CCNB1 和 mTOR 通路,促进肿瘤进展。
Sci Rep. 2024 Jun 28;14(1):14914. doi: 10.1038/s41598-024-66020-1.
10
Increased expression of fibroblast growth factor 13 in prostate cancer is associated with shortened time to biochemical recurrence after radical prostatectomy.前列腺癌中,成纤维细胞生长因子13表达增加与前列腺癌根治术后生化复发时间缩短相关。
Int J Cancer. 2016 Jul 1;139(1):140-52. doi: 10.1002/ijc.30048. Epub 2016 Mar 12.

引用本文的文献

1
Urea Transporters and Their Gene Mutations in Diseases.疾病中的尿素转运蛋白及其基因突变
Subcell Biochem. 2025;118:127-140. doi: 10.1007/978-981-96-6898-4_7.
2
WGCNA-ML-MR integration: uncovering immune-related genes in prostate cancer.加权基因共表达网络分析-机器学习-孟德尔随机化整合:揭示前列腺癌中的免疫相关基因
Front Oncol. 2025 Apr 7;15:1534612. doi: 10.3389/fonc.2025.1534612. eCollection 2025.
3
Roles and therapeutic potential of the SLC family in prostate cancer-literature review.SLC家族在前列腺癌中的作用及治疗潜力——文献综述

本文引用的文献

1
KEGG: integrating viruses and cellular organisms.KEGG:整合病毒和细胞生物。
Nucleic Acids Res. 2021 Jan 8;49(D1):D545-D551. doi: 10.1093/nar/gkaa970.
2
Overexpression levels of cripto-1 predict poor prognosis in patients with prostate cancer following radical prostatectomy.在接受根治性前列腺切除术后的前列腺癌患者中,cripto-1的过表达水平预示着预后不良。
Oncol Lett. 2019 Sep;18(3):2584-2591. doi: 10.3892/ol.2019.10555. Epub 2019 Jul 4.
3
Toward understanding the origin and evolution of cellular organisms.为了理解细胞生物的起源和进化。
BMC Urol. 2025 Feb 18;25(1):32. doi: 10.1186/s12894-025-01714-w.
4
Identification and validation of diagnostic and prognostic biomarkers in prostate cancer based on WGCNA.基于加权基因共表达网络分析的前列腺癌诊断和预后生物标志物的鉴定与验证
Discov Oncol. 2024 Sep 21;15(1):131. doi: 10.1007/s12672-024-00983-5.
5
SLC14A1 and TGF-β signaling: a feedback loop driving EMT and colorectal cancer metachronous liver metastasis.溶质载体家族 14 成员 1(SLC14A1)和转化生长因子-β(TGF-β)信号:驱动 EMT 和结直肠癌肝转移的反馈环。
J Exp Clin Cancer Res. 2024 Jul 27;43(1):208. doi: 10.1186/s13046-024-03114-8.
6
Down-regulation of SLC14A1 in prostate cancer activates CDK1/CCNB1 and mTOR pathways and promotes tumor progression.前列腺癌细胞中 SLC14A1 的下调激活 CDK1/CCNB1 和 mTOR 通路,促进肿瘤进展。
Sci Rep. 2024 Jun 28;14(1):14914. doi: 10.1038/s41598-024-66020-1.
7
Aspartate β-hydroxylase Regulates Expression of Genes.天冬氨酸β-羟化酶调节基因表达。
J Cancer. 2024 Jan 1;15(5):1138-1152. doi: 10.7150/jca.90422. eCollection 2024.
Protein Sci. 2019 Nov;28(11):1947-1951. doi: 10.1002/pro.3715. Epub 2019 Sep 9.
4
MicroRNA-508 is downregulated in clear cell renal cell carcinoma and targets ZEB1 to suppress cell proliferation and invasion.微小RNA-508在肾透明细胞癌中表达下调,并靶向锌指E盒结合蛋白1以抑制细胞增殖和侵袭。
Exp Ther Med. 2019 May;17(5):3814-3822. doi: 10.3892/etm.2019.7332. Epub 2019 Mar 1.
5
Cancer statistics, 2019.癌症统计数据,2019 年。
CA Cancer J Clin. 2019 Jan;69(1):7-34. doi: 10.3322/caac.21551. Epub 2019 Jan 8.
6
Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.根治性治疗后生化复发对前列腺癌预后的价值:系统评价。
Eur Urol. 2019 Jun;75(6):967-987. doi: 10.1016/j.eururo.2018.10.011. Epub 2018 Oct 17.
7
Potential role of rituximab in metastatic castrate-resistant prostate cancer.利妥昔单抗在转移性去势抵抗性前列腺癌中的潜在作用。
J Oncol Pharm Pract. 2019 Sep;25(6):1509-1511. doi: 10.1177/1078155218790338. Epub 2018 Aug 9.
8
Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy.前列腺癌阿比特龙和恩杂鲁胺耐药患者来源模型揭示了对核糖体导向治疗的敏感性。
Eur Urol. 2018 Nov;74(5):562-572. doi: 10.1016/j.eururo.2018.06.020. Epub 2018 Jul 23.
9
Modeling the role of microRNA-449a in the regulation of the G2/M cell cycle checkpoint in prostate LNCaP cells under ionizing radiation.建立 miRNA-449a 在前列腺 LNCaP 细胞中调控电离辐射诱导的 G2/M 细胞周期检验点的模型。
PLoS One. 2018 Jul 19;13(7):e0200768. doi: 10.1371/journal.pone.0200768. eCollection 2018.
10
MicroRNA-508 suppresses epithelial-mesenchymal transition, migration, and invasion of ovarian cancer cells through the MAPK1/ERK signaling pathway.微小 RNA-508 通过 MAPK1/ERK 信号通路抑制卵巢癌细胞上皮-间充质转化、迁移和侵袭。
J Cell Biochem. 2018 Sep;119(9):7431-7440. doi: 10.1002/jcb.27052. Epub 2018 May 21.